Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay Kumar Shukla

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
British Journal of Clinical Pharmacology|March 23, 2019
Consensi: Is it a conscientious combination?Ajay Kumar Shukla, Ratinder Jhaj
Journal of Basic and Clinical Physiology and Pharmacology|April 15, 2022
An overview of post COVID sequelaeAjay Kumar Shukla, Saurav Misra
European Journal of Clinical Pharmacology|April 2, 2023
Teplizumab: type 1 diabetes mellitus preventable?Saurav Misra, Ajay Kumar Shukla
Indian Journal of Public Health|December 31, 2025
Trends and Insights in Biological Drug Approvals by the US Food and Drug Administration: 2013-2022Ajay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology|May 3, 2022
Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemicAjay Kumar Shukla, Saurav Misra
Journal of Pharmacy & Bioallied Sciences|July 11, 2025
A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational StudyAjay Kumar Shukla, Saurav Misra
Journal of General Internal Medicine|March 1, 2023
The Use of Ivermectin in the Treatment of COVID-19Ajay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology|December 6, 2023
Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's diseaseAjay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology|January 7, 2022
Antibody-dependent enhancement of virus infection and disease: implications in COVID-19Ajay Kumar Shukla, Saurav Misra
Journal of Family Medicine and Primary Care|October 18, 2021
Clinical inertia in elderly for vaccinationAjay Kumar Shukla, Saurav Misra
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|March 23, 2019
Consensi: Is it a conscientious combination?Ajay Kumar Shukla, Ratinder Jhaj
Journal of Basic and Clinical Physiology and Pharmacology|April 15, 2022
An overview of post COVID sequelaeAjay Kumar Shukla, Saurav Misra
European Journal of Clinical Pharmacology|April 2, 2023
Teplizumab: type 1 diabetes mellitus preventable?Saurav Misra, Ajay Kumar Shukla
Indian Journal of Public Health|December 31, 2025
Trends and Insights in Biological Drug Approvals by the US Food and Drug Administration: 2013-2022Ajay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology|May 3, 2022
Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemicAjay Kumar Shukla, Saurav Misra
Journal of Pharmacy & Bioallied Sciences|July 11, 2025
A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational StudyAjay Kumar Shukla, Saurav Misra
Journal of General Internal Medicine|March 1, 2023
The Use of Ivermectin in the Treatment of COVID-19Ajay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology|December 6, 2023
Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's diseaseAjay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology|January 7, 2022
Antibody-dependent enhancement of virus infection and disease: implications in COVID-19Ajay Kumar Shukla, Saurav Misra
Journal of Family Medicine and Primary Care|October 18, 2021
Clinical inertia in elderly for vaccinationAjay Kumar Shukla, Saurav Misra
Pageof 3